OVERVIEW

The Emerging Role of Drug Eluting Stents in the Treatment of Complex Coronary Lesions is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Dec 22, 2017 - Dec 22, 2019.

Intended Learners:
This activity is designed for interventional cardiologists, vascular surgeons, interventional radiologists, cardiothoracic surgeons, clinical cardiologists, nurses, technicians and others involved in the treatment of complex coronary lesions.

Accreditation:
CME: NACCME designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

CNE: This continuing nursing education activity awards 1.0 contact hour. Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.

CPME: NACCME is approved by the Council on Podiatric Medical Education as a provider of continuing education in podiatric medicine. NACCME has approved this activity for a maximum of 1.0 continuing education contact hour.

ARRT: Robotic Utilization in CLI in 2018: Protect Your Staff, Protect Yourself has been approved for 1 ARRT Category A CE credit by AHRA

Learning Objectives:
After Completing This Activity, Participants Should Be Able To:
• Compare and contrast emerging technologies used to treat complex coronary lesions
• Identify current drug-eluting stents approved for the treatment of complex coronary lesions
• Assess the long-term outcomes of drug-eluting stents vs. bare metal stents, and identify the best stenting options for patients.